Search Results
Your search for Julie Vose, MD, MBA, FASCO,Julie Vose, MD, MBA, FASCO matches 84 pages
Showing 51 - 84ASCO Praises President for White House’s Support of ‘Moonshot’ Initiative
On January 28, 2016, ASCO released the following statement by ASCO President Julie M. Vose, MD, MBA, FASCO: ASCO applauds President Obama for aligning the Administration’s full support behind Vice President Biden’s “moonshot” initiative to accelerate the discovery of new cancer treatments, as...
ASCO Names Advance of the Year, Highlights Major Top Research Trends
Research is the bedrock of progress against cancer, and discoveries in cancer biology are moving from bench to bedside faster than ever. No recent advance has been more transformative than the rise of immunotherapy, particularly over the past year, making this treatment strategy ASCO’s Advance of...
ASCO Names Cancer Advance of the Year: Immunotherapy
At a Capitol Hill briefing today, ASCO announced immunotherapy as the top cancer advance of the year. Recent breakthroughs in immunotherapy—along with almost 60 other important cancer research advances—are described in ASCO's just-released report, Clinical Cancer Advances 2016: ASCO's...
Julie M. Vose, MD, MBA, FASCO, on Nivolumab in Relapsed/Refractory Hodgkin Lymphoma
Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 289, “Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma: Preliminary Safety, Efficacy, and Biomarker Results of a Phase I Study,” presented by Philippe Armand, MD, PhD.
Julie M. Vose, MD, MBA, FASCO, on Ublituximab Plus TGR-1202 in Lymphoma
Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 801, “Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination With TGR-1202, a Next-Generation Once-Daily PI3kδ Inhibitor, Demonstrates Activity in Heavily...
Julie M. Vose, MD, MBA, FASCO, on the AETHERA trial
Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 673, “The AETHERA Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following...
ASCO Submits Comments to CMS on EHR Stage 3 of Meaningful Use and Modifications Final Rule
On December 15, ASCO submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the agency’s Electronic Health Record (EHR) Stage 3 of Meaningful Use and Modifications in 2015 through 2017. The Society’s comments provided recommendations to CMS regarding the implementation of...
Conquer Cancer Foundation Hosts Inaugural Scientific and Career Development Retreat
In October 2015, the Conquer Cancer Foundation of ASCO (CCF) hosted its first Scientific and Career Development Retreat at ASCO Headquarters in Alexandria, Virginia, for past recipients of the Young Investigator Award (YIA) and Career Development Award (CDA). The YIA provides funding to promising...
ASCO Calls for Improvements to Clinical Pathway Programs in Oncology
ASCO released a new policy statement with recommendations to ensure that clinical pathways in oncology promote—not hinder—the care of patients with cancer. Published by Zon et al in the Journal of Oncology Practice, the statement asserts that the way in which these treatment management...
Dr. Julie Vose Finds the Best of Both Worlds—Patient Care and Cutting-Edge Research—in Academic Medicine
Julie M. Vose, MD, MBA, is the Neumann M. and Mildred E. Harris Professor and Chief of the Division of Hematology/Oncology at the University of Nebraska Medical Center. She grew up in Mitchell, South Dakota, a small town nestled on the banks of the James River. Mitchell is home to the Corn Palace,...
Society Announces Candidates for ASCO Election
Fourteen distinguished ASCO members have been selected by the ASCO Nominating Committee as candidates for open leadership positions within the Society for the 2014 ASCO Election. Biographic information and interviews with each candidate, as well as instructions for casting a proxy ballot, will be...
ASCO President-Elect Candidate Julie M. Vose, MD, MBA, FASCO
Cost of Care and Federal Funding How can ASCO address the high cost of cancer care and diminishing federal resources for basic and translational research? We need to work with the Centers for Medicare & Medicaid Services, private insurers, and health-care systems to encourage evidence-based...
President-Elect Candidates Address ASCO's Challenges and Opportunities in the Coming Decades
In September, ASCO announced the names of 14 ASCO members who have been selected by the ASCO Nominating Committee as candidates for open leadership positions within the Society for the 2014 ASCO Election. The two candidates nominated for President-Elect are Lynn M. Schuchter, MD, FASCO, and Julie...
ASCO Announces Election Results for Terms Beginning June 2014
In addition to the election of Julie M. Vose, MD, MBA, FASCO, as President of the American Society of Clinical Oncology (ASCO) for a 1-year term beginning in June 2015 (see page 85), ASCO has announced four new members who were recently elected to the ASCO Board of Directors and two new members...
Julie M. Vose, MD, MBA, FASCO, Elected ASCO President for 2015–2016 Term
Julie M. Vose, MD, MBA, FASCO, has been elected President of ASCO for a 1-year term beginning in June 2015. She will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2014. “ASCO is a very diverse and multifaceted organization with so much to offer its membership. The ...
ASCO Honors New Group of Members With FASCO Distinction
Formerly called the ASCO Statesman Award, the Fellow of the American Society of Clinical Oncology (FASCO) distinction recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO. Their efforts benefit ASCO, the specialty of oncology, and, most importantly,...
American Society of Clinical Oncology Honors Researchers, Patient Advocates, and Leaders of the Global Oncology Community
Leaders in cancer care will be recognized as part of the American Society of Clinical Oncology Special Awards Program at the 2014 ASCO Annual Meeting. The Special Awards recognize the dedication and significant contributions of researchers, patient advocates, and leaders of the global oncology...
Reflecting on the Past Year and Looking Ahead to the Next
On assuming the Presidency of ASCO a year ago, I recognized that one of our greatest challenges as a professional society is helping the American public understand the value of cancer research, especially now, when scientific advances are accelerating but resources are contracting. This is partly...
The Power of Laughter
The following essay by Julie Vose, MD, MBA, FASCO, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories (May 2014), coedited by Stan Winokur, MD, and Vincent Coppola. The book is available on Amazon.com and thebigcasino.org. When I met Cindy, she was...
Second Annual JADPRO Live Conference Attracts 400 Advanced Practitioners in Oncology From Across the Nation
The second annual JADPRO Live: Transforming Oncology Practice was held October 30 to November 2 in Orlando, Florida. The conference drew nearly 400 nurse practitioners, physician assistants, clinical nurse specialists, advanced-degree nurses, hematology/oncology nurses, pharmacists, and...
Beating the Odds in The Big Casino
More than 35 ASCO members contributed personal essays to a recently published collection of stories about humanism in medicine, including ASCO Past Presidents Paul A. Bunn, Jr, MD, FASCO, and Emil J. Freireich, MD, FASCO, and current President-Elect Julie M. Vose, MD, MBA, FASCO. The Big Casino:...
Profile: Julie M. Vose, MD, MBA, FASCO, Making a Difference in Both Clinical Medicine and Research
At this year’s ASCO Annual Meeting, Julie M. Vose, MD, MBA, FASCO, will begin her term as the Society’s 51st President. It is fitting that the meeting will be held in Chicago, the city where the first seven visionaries met over lunch in 1964 to formulate a medical organization centered on cancer...
2015–2016 ASCO President Julie M. Vose, MD, MBA, FASCO: Leading During a Year of Historic Changes
Julie M. Vose, MD, MBA, FASCO, began her term as the 2015–2016 President of ASCO at the 2015 Annual Meeting on June 1, 2015. Dr. Vose, a leading expert in the treatment of patients with lymphoma, is the current Neumann M. and Mildred E. Harris Professorial Chair and Chief of the Oncology/Hematology ...
Collective Wisdom: Patient-Centered Care and Research
In 1964, when the first seven physicians who founded ASCO met, I doubt they imagined what a successful Society they were forming. At that time, cancer treatments were just beginning to have some early successes with a few cytotoxic therapies, new radiation modalities, and improved surgical...
Our Patients Are the True Heroes of Cancer Research
A few weeks ago, I read an op-ed1 in The New York Times written by Stan Collender, a patient with Merkel cell carcinoma, a rare and aggressive type of skin cancer. In his article, he described his participation in a clinical trial for a new drug he is hoping will stem progression of his cancer and...
ASCO Asks CMS to Revisit Its Payment Policy to Support Optimal Cancer Care
ASCO has called on the Centers for Medicare & Medicaid Services (CMS) to reconsider revisions to payment policies that could be administratively burdensome to oncology practices and result in reimbursement that inadequately supports optimal cancer patient care. In a comment letter to CMS on...
Community Research Forum Holds 2015 Annual Meeting, Explores Developments and Strategies in Conducting Clinical Research
ASCO’s Community Research Forum (CRF) held its 2015 Annual Meeting September 20–21 at ASCO Headquarters in Alexandria, Virginia. Over 75 physician investigators, program directors, and research staff attended the meeting, representing a wide range of community-based practices and research sites...
Journal of Clinical Oncology’s Fall Special Series, Journal of Global Oncology’s Inaugural Issue
This fall, the Journal of Clinical Oncology (JCO) presented two special series: “Pediatric Cancer—Progress Through Collaboration” and “Head and Neck Cancer: Recent Advances, Changing Epidemiology, and Future Directions.” The Pediatric Special Series highlighted collaborative efforts that have...
ASCO Calls for Comprehensive Payment Reform to Address Issue of Site Neutrality
ASCO recently called for comprehensive physician payment reform to support the full scope of services required by patients with cancer, rather than jeopardizing patient outcomes by reducing the available resources in a particular cancer care setting in an effort to achieve “site neutrality” in...
The Importance of Supporting the Role of Women Leaders in Oncology
I am honored to be the 52nd President of ASCO and thrilled to have followed in the steps of six remarkable women to hold this important leadership position in a professional Society that represents nearly 40,000 oncologists around the world caring for people with cancer. My six female predecessors...
ASCO Calls for Comprehensive Payment Reform to Address Issue of Site Neutrality
ASCO has called for comprehensive physician payment reform to support the full scope of services required by patients with cancer, rather than jeopardizing patient outcomes by reducing the available resources in a particular cancer care setting in an effort to achieve "site neutrality" in...
ASCO Releases Updated Policy Statement on Genetic and Genomic Testing for Cancer Susceptibility
The American Society of Clinical Oncology (ASCO) issued an updated policy statement on genetic and genomic testing for cancer susceptibility. Published in the Journal of Clinical Oncology, the statement reviews the ways in which new technologies are transforming the assessment and identification of ...
ASCO Publishes Conceptual Framework to Assess the Value of New Cancer Treatment Options
In a press conference today, ASCO detailed the contents of the initial version of a conceptual framework for assessing the value of new cancer treatment options based on the treatment’s clinical benefit, side effects, and cost. Other important measures, such as quality of life and...
Julie M. Vose, MD, MBA, FASCO, Elected ASCO President for 2015-2016 Term
Julie M. Vose, MD, MBA, FASCO, has been elected President of the American Society of Clinical Oncology (ASCO) for a 1-year term beginning in June 2015. She will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2014. Additionally, four new members were elected to the...
